NEW YORK, Oct. 29 (GenomeWeb News) - Beckman today reported sales of $581 million for the third quarter, up over $535 million one year ago.
The company's Biomedical Research Division, which sells the GenomeLab and ProteomeLab instruments, increased by 5 percent year over year. Clinical Diagnostics, by comparison, was up 10 percent.
R&D spending for the period increased to $51.5 million from $46.5 million. Net earnings for the quarter jumped to $57 million, or $.93 per basic earnings per share, from $40 million, or $.65 per basic earnings per share, for the same quarter in 2003.
The company reported cash and cash equivalents of $31 million on hand as of Sept. 30.